High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer

Fu, X. ✉; Pereira, R.; Liu, C.-C.; De, Angelis C.; Shea, M.J.; Nanda, S.; Qin, L.; Mitchell, T.; Cataldo, M.L.; Veeraraghavan, J.; Sethunath, V.; Giuliano, M.; Gutierrez, C.; Győrffy, B. [Győrffy, Balázs (Onkológia), szerző] Onkológiai Biomarker Kutatócsoport (Lendület) (HRN TTK / MÉI); Bioinformatika Tanszék (SE / AOK / I); Trivedi, M.V.; Cohen, O.; Wagle, N.; Nardone, A.; Jeselsohn, R.; Rimawi, M.F.; Osborne, C.K.; Schiff, R. ✉

Angol nyelvű Szakcikk (Folyóiratcikk) Tudományos
Megjelent: CELL REPORTS 2639-1856 2211-1247 42 (8) Paper: 112821 , 28 p. 2023
  • SJR Scopus - Biochemistry, Genetics and Molecular Biology (miscellaneous): D1
Azonosítók
Támogatások:
  • (2020-4.1.1.-TKP2020)
Aberrant activation of the forkhead protein FOXA1 is observed in advanced hormone-related cancers. However, the key mediators of high FOXA1 signaling remain elusive. We demonstrate that ectopic high FOXA1 (H-FOXA1) expression promotes estrogen receptor-positive (ER+) breast cancer (BC) metastasis in a xenograft mouse model. Mechanistically, H-FOXA1 reprograms ER-chromatin binding to elicit a core gene signature (CGS) enriched in ER+ endocrine-resistant (EndoR) cells. We identify Secretome14, a CGS subset encoding ER-dependent cancer secretory proteins, as a strong predictor for poor outcomes of ER+ BC. It is elevated in ER+ metastases vs. primary tumors, irrespective of ESR1 mutations. Genomic ER binding near Secretome14 genes is also increased in mutant ER-expressing or mitogen-treated ER+ BC cells and in ER+ metastatic vs. primary tumors, suggesting a convergent pathway including high growth factor receptor signaling in activating pro-metastatic secretome genes. Our findings uncover H-FOXA1-induced ER reprogramming that drives EndoR and metastasis partly via an H-FOXA1/ER-dependent secretome. © 2023 The Authors
Hivatkozás stílusok: IEEEACMAPAChicagoHarvardCSLMásolásNyomtatás
2025-03-30 09:17